Incidence of cardiovascular disease and death in patients receiving diethylstilbestrol for carcinoma of the prostate.
D000135:Acid Phosphatase / Q000097:blood; D000368:Aged; D002277:Carcinoma / Q000188:drug therapy* / Q000401:mortality; D002318:Cardiovascular Diseases / Q000139:chemically induced* / Q000150:complications / Q000401:mortality; D002561:Cerebrovascular Disorders / Q000150:complications; D002986:Clinical Trials as Topic; D004054:Diethylstilbestrol / Q000009:adverse effects*; D004562:Electrocardiography; D006333:Heart Failure / Q000150:complications; D006801:Humans; D007511:Ischemia / Q000150:complications; D008297:Male; D009203:Myocardial Infarction / Q000150:complications; D009362:Neoplasm Metastasis; D010919:Placebos; D010958:Plasminogen / Q000378:metabolism; D011379:Prognosis; D011467:Prostate / Q000378:metabolism; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000401:mortality; D011655:Pulmonary Embolism / Q000150:complications
D010919:Placebos; D004054:Diethylstilbestrol; D010958:Plasminogen; D000135:Acid Phosphatase